Amid controversies and news of expedited trials abroad, the latest report surrounding Sputnik V suggests that the vaccine is able to live upto its promised aim, and delivers tolerable immunity after the first shot. Alexander Gintsburg, the head of Moscow’s state-run Gamaleya research institute, heading the trials said that enough samples have been observed to conclude the safe workings of the vaccine. He also added that an additional dose would only be required to ‘extend’ the immunity period. Howeverit is unclear as to how long would the first bout of immunity last:

“For some, the protective level of antibodies is produced after the first vaccination and they need the second one to extend that protection. They will likely be protected two weeks after the first vaccination,” Gintsburg also stated that the chances of reinfection, post-vaccination are likely to be “low” or “weak”.

“If there is [an infection between the first and second shots], it will occur in a weaker form.”

Russia is in the middle of country-wide inoculation. First batches of the vaccine have been made ready to be administered to essential workers first. Talks have also been made with India, with pharma giant, Dr Reddy’s all set to bring the vaccine to India, produce ample doses for the public after it goes through phase III trials, clearances and required nods from the DGCI. As per reports, the administration could start as early as January next year.